News

The Director of Policy and Advocacy for the US Pain Foundation addresses the important changes made to the updated draft of the CDC Clinical Practical Guideline for Prescribing Opioids 2022.

“Understanding the impact of axSpA on pregnancy outcomes is a vital component of improving management of women with axSpA at every stage of their lives,” investigators stated.

Authors of the study on PRP in knee osteoarthritis addressed the concerns shared by physicians in response to the method of their research.

Treat-to-target is a key strategy used in the treatment of many chronic conditions. Test your knowledge of its use in rheumatoid arthritis.

Because Sjögren's Syndrome is often undetected or misdiagnosed, investigators developed the Sjögren's Syndrome Screening Questionnaire (SSSQ).

New data support the continued assessment of the investigative drug for adults with SLE.

Investigators in Israel perform the largest retrospective review of patients with rheumatic fever in a developed country, spanning 25 years of research.

The results lead investigators to question the usefulness of prehabilitation before total knee replacement to improve functional outcomes in patients with osteoarthritis.

“Incorporating patient perspectives will not only help better tailor therapies in this heterogeneous population but also identify treatment targets that are relevant to the individual patients," investigators explained.

ACR partners with the Vasculitis Foundation to establish a new guideline that addresses diagnostic issues relating to Kawasaki disease, a rare vasculitis that inflames the blood vessels.

With several targeted therapies demonstrating positive trial results in lupus nephritis, the treatment paradigm appears to be shifting.

“Access to mental health services is a critical component of comprehensive care for patients suffering from rheumatologic disease,” investigators stated.

Methotrexate is the first-line treatment for rheumatoid arthritis. As with all drugs, there is a risk of experiencing adverse effects. Do you know what type of adverse effects are most likely with methotrexate and who is likely to experience them? Take this quiz to find out.

Karen Onel, MD, one of the lead investigators of the ACR's recent JIA treatment guidelines updates, explains important changes, treating patients with glucocorticoids, and the continued unmet needs in pediatric rheumatology.

Free or total 25(OH)D serum levels were not associated with psoriasis disease severity in this small study of biologic-naïve patients.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 12, 2021.

Investigators examined the effect that pulsed low-intensity ultrasonography had on symptom relief and tibiofemoral articular cartilage thickness among patients with knee osteoarthritis.

Trauma patients and patients treated with combination ABX therapy were at an increased risk of C difficile infections.

“Kawasaki disease continues to be an area of evolving understanding in clinical treatment,” said Mark Gorelik, MD, lead investigator of the guideline.

More than 50% of patients with classified SLE at Washington University’s Lupus Clinic exhibit clinically meaningful and persistent depression and anxiety symptoms over time.

Titled, "Biosimilars in Rheumatology: Past, Present, and Future," this 3-part video series explores the origins of biosimilars, where we are currently, and hypothesizes about the future of biosimilars in the United States.

In this Q&A, Krzysztof Bonek, MD, PhD, discussed the findings of his study that looked at the associations of IL-18 serum levels with serum lipids, cardiovascular risk and disease activity in patients with ankylosing spondylitis and psoriatic arthritis.

When patients undergo surgery for hip and knee replacements, adjustment to their rheumatoid arthritis care may be required. Test your knowledge of how to manage patients undergoing these types of surgery in this quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 5, 2021.

The American College of Rheumatology (ACR) has published guidance regarding the management of juvenile idiopathic arthritis, with emphasis placed on the treatment of systemic JIA and oligoarthritis, as well as non-pharmacologic therapies.

The American College of Rheumatology releases 2 new guidelines for treating patients with juvenile idiopathic arthritis.

Aspartyl-alanyl-diketopiperazine (Ampion), an intra-articular injection, works to regulate immune responses that are connected to pain, inflammation, and joint damage in patients with osteoarthritis of the knee.

In rheumatoid arthritis, a treat-to-target approach aims for remission or low disease activity within the first 3 months. However, investigators noted that improvements continued to increase throughout the 52-week period.

New recommendations were released by ACR and AAHKS regarding perioperative management of antirheumatic medications for patients with rheumatic diseases undergoing these procedures.

"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."